Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

ABSTRACT:

Objective

A double-blind, randomized, controlled study was undertaken to determine whether combined use of interferon β-1a (IFN) 30 μg intramuscularly weekly and glatiramer acetate (GA) 20 mg daily is more efficacious than either agent alone in relapsing-remitting multiple sclerosis.

Methods

A total of 1,008 participants were randomized and followed until the last participant enrolled completed 3 years. The primary endpoint was reduction in annualized relapse rate utilizing a strict definition of relapse. Secondary outcomes included time to confirmed disability, Multiple Sclerosis Functional Composite (MSFC) score, and magnetic resonance imaging (MRI) metrics.

Results

Combination IFN+GA was not superior to the better of the single agents (GA) in risk of relapse. Both

SUBMITTER: Lublin FD 

PROVIDER: S-EPMC3631288 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature